BRAF and benign thyroid gland neoplasm: Previous studies have found the BRAF T1799A mutation in approximately 45% of PTC and 25% of apparently PTC-derived anaplastic thyroid cancers, but not in follicular thyroid cancer (FTC) and benign thyroid tumors [77].